

# UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

		FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
APPLICATION NO.	11/03/97	LEVY	D	10401/1
08/962,740	11/02/			

HM31/1221

**EXAMINER** 

KENYON & KENYON ONE BROADWAY NEW YORK NY 10004 LANKFORD JR,L

PAPER NUMBER ART UNIT 1651

DATE MAILED:

12/21/98

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 



### Office Action Summary

Application No. 08/962,740

Applicant(s)

Levy et al

Examiner

L. Blaine Lankford

Group Art Unit

1651 -

This action is FINAL.	and metters procedution as to the merits is closed
Since this application is in condition for allowance except for f in accordance with the practice under <i>Ex parte Quayle</i> , 1935	C.D. 11; 403 O.G. 213.
a shortened statutory period for response to this action is set to a solution solution. Failure to pplication to become abandoned. (35 U.S.C. § 133). Extension (7 CFR 1.136(a).	THE COUNTY WILLIAM CITE DOLLOG TOLLOG POLICE
Disposition of Claims	talana analisa in the positionian
	is/are pending in the application.
Of the above, claim(s) 6-34	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
X Claim(s) 1-5	is/are rejected.
Claim(s)	is/are objected to.
Claims	are subject to restriction or election requirement.
Application Papers  See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
☐ The drawing(s) filed on is/are objected	ed to by the Examiner.
☐ The proposed drawing correction, filed on	is approved disapproved.
☐ The proposed drawing correction, filed on  ☐ The specification is objected to by the Examiner.	
☐ The specification is objected to by the Examiner. ☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign priority to	ınder 35 U.S.C. § 119(a)-(d).
☐ Acknowledgement is made of a claim for foreign phonty to ☐ All ☐ Some* ☐ None of the CERTIFIED copies of	the priority documents have been
☐ All ☐ Some* ☐ None of the CENTIFIED copies of	
☐ received. ☐ received in Application No. (Series Code/Serial Num	nber)
received in Application No. (Solids Solids) received in this national stage application from the	International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priorit	y under 35 U.S.C. § 119(e).
Attachment(s)  Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No.	o(s)
☐ Interview Summary, PTO-413	
Notice of Draftsperson's Patent Drawing Review, PTO-94	8
☐ Notice of Informal Patent Application, PTO-152	
	THE FOLLOWING PAGES

Art Unit: 1651

### **DETAILED ACTION**

#### Election/Restriction

Applicant's election with traverse of claims 1-5 in Paper No. 5 is acknowledged. The traversal is on the ground(s) that the examination of both groups would not be burdensome. This is not found persuasive because the issues and searches for the two groups are greatly divergent.

The requirement is still deemed proper and is therefore made FINAL.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-5 imply that other cell lines with the claim designated properties can be found using the method disclosed in the specification without undue experimentation.

Application/Control Number: 08/962,740 Page 3

Art Unit: 1651

Whether a specification complies with the written description requirement of § 112, first paragraph, is a question of fact *Vas-Cath Inc. v. Mahurkar*, 935 F.2d 1555, 1563, 19 USPQ2d 1111, 1116 (Fed. Cir. 1991); *Ralston Purina Co. v. Far-Mar-Co, Inc.*, 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985). To fulfill the written description requirement, a specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) ("[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, the written description requirement is satisfied "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of the desired cell line "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, an adequate written description of the desired cell line requires more than a mere statement that it is part of the invention because it has a desired functional property and reference to a potential method for finding it; what is required is a description of the cell line itself.

Art Unit: 1651

Whether or not the disclosure provides an enabling disclosure, it does not provide a written description of the desired cell lines which is necessary to provide a written description of the cell lines of claims 1-5. The functional property is not itself a written description of that cell line, it conveys no distinguishing information concerning its identity, just its functional property. While the disclosure provides a process for obtaining an additional cell lines with the claimed properties, there is no further information in the application pertaining to the desired organisms characteristics; in other words, it does not describe cell lines having the desired functional property in general. Describing a method of finding a suitable cell line having the desired functional property, as in the example, does not necessarily describe the desired cell line itself.

Every species in a genus need not be described in order that a genus meet the written description requirement. See *Utter*, 845 F.2d at 998- 99, 6 USPQ2d at 1714 ("A specification may, within the meaning of § 112, first paragraph, contain a written description of a broadly claimed invention without describing all species that claim encompasses.") In claims to an species of cell line from a genus, however, a generic statement without more, is not an adequate written description of the genus because it does not distinguish the claimed species of the genus from others, except by the alleged function of degrading moniliformin. It does not specifically define any of the species of that genus that fall within its definition. It does not define any features (as commonly used in the art of microbiology) which are commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. A

Art Unit: 1651

definition by function, does not suffice to define the genus because it is only an indication of what the genus does, rather than what it is. See *Fiers*, 984 F.2d at 1169-71, 25 USPQ2d at 1605-06 (discussing Amgen). It is only a definition of a useful result rather than a definition of what achieves that result. Many such species of the genus may achieve that result. The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material.

Claims 1-5 are essentially of limitless breadth. It is implied that so long as the specification provides one with the ability to test any particular embodiment which is encompassed by the material limitations of a claim, one can thereby distinguish between those embodiments which meet the functional limitations from those embodiments which don't. This argument is not entirely without merit. However, the issue here is the breadth of the claims in light of the predictability of the art as determined by the number of working examples, the skill level of the artisan and the guidance presented in the instant specification and the prior art of record. This 'make and test' position is inconsistent with the decisions in *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970), *Amgen v. Chugai Pharmaceuticals Co. Ltd.*, 13 USPQ2d, 1737 (1990),

Application/Control Number: 08/962,740 Page 6

Art Unit: 1651

and *In re Wands*, 8 USPQ2d, 1400 (CAFC 1988). *In re Wands* stated that the factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and, (8) the breadth of the claims.

Breadth alone is not the issue, however. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970), held that

"Inventor should be allowed to dominate future patentable inventions of others where those inventions were based in some way on his teachings, since such improvements while unobvious from his teachings, are still within his contribution, since improvement was made possible by his work; however, he must not be permitted to achieve this dominance by claims which are insufficiently supported and, hence, not in compliance with first paragraph of 35 U.S.C. 112; that paragraph requires that scope of claims must bear a reasonable correlation to scope of enablement provided by specification to persons of ordinary skill in the art; in cases involving predictable factors, such as mechanical or electrical elements, a single embodiment provides broad enablement in the sense that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to known scientific law; in cases involving unpredictable factors, such as most

Application/Control Number: 08/962,740 Page 7

Art Unit: 1651

chemical reactions and physiological activity, scope of enablement varies inversely with degree of unpredictability of factors involved."

Having established the breadth of the claims, *Wands* now requires that one consider the number of working examples presented in the instant specification.

The premise that the standard under 35 U.S.C. § 112, first paragraph, is that of isolating a subject cell line and testing to see if it obtains the desired biological activity is a position that has been routinely dismissed by the courts, as shown by those decisions cited above.

The breadth of claims must be based upon the predictability of the claimed subject matter and not on some standard of trial and error. To argue that one can make material embodiments of the invention and then test for those that work in the manner disclosed or that the instant claims only encompass the working embodiments is judicially unsound. Unless one has a **reasonable expectation** that any one material embodiment of the claimed invention would be more likely than not to function in the manner disclosed or the instant specification provides sufficient guidance to permit one to identify those embodiments which are **more likely to work that not** without actually making and testing them then the instant application does not support the breadth of the claims. In the instant case it is highly improbable that any cell line will more likely than not perform in the manner disclosed and the instant specification does not provide the guidance needed to find other cell lines with the desired functional property with any reasonable expectation that such cell lines will be found.

1. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as not enabling the claimed invention.

The following objection relates to the non-enabling disclosure.

Page 8 Application/Control Number: 08/962,740 Art Unit: 1651 It is apparent that the cell lines are required to practice the claimed invention. As a required element it must be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If the cell line is not so obtainable or available, the requirements of 35 USC 112 may be satisfied by a deposit of the cell line. See 37 C.F.R. 1.802. If the deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by applicants, or a statement by an attorney of record over his or her signature and registration number, stating that the specific strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein. If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 CFR 1.801-1.809, applicants may provide assurance of compliance by an affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that: (a) during the pendency of this application, access to the invention will be afforded to one determined by the Commissioner to be entitled thereto; (b) all restrictions imposed by the depositor upon availability to the public will be irrevocably removed upon granting of the patent; (c) the deposit will be maintained in a public depository for a period of at least thirty years or at least five years after the most recent request for the furnishing of a sample of the deposited material;

Art Unit: 1651

(d) a viability statement in accordance with the provisions of 37 C.F.R. 1.807: and

(e) the deposit will be replaced should it become necessary due to inviability, contamination or loss of capability to function in the manner described in the specification.

In addition the identifying information set forth in 37 C.F.R. 1.809(d) should be added to the specification. See 37 C.F.R. 1803-1.809 for additional explanation of these requirements.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blaine Lankford whose telephone number is (703) 308-2455.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Withyshyn, can be reached on (703) 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

December 21, 1998

L. Blaine Lankford **Primary Examiner** 

Art Unit 1651